A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms UNITY 1
- Sponsors Bristol-Myers Squibb
- 02 Apr 2022 Planned number of patients changed from 400 to 460.
- 07 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Mar 2014 Planned End Date changed from 1 Dec 2014 to 1 Oct 2014 according to ClinicalTrial.gov record .